These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1112 related articles for article (PubMed ID: 27456970)

  • 1. Comparison of the HER2, estrogen and progesterone receptor expression profile of primary tumor, metastases and circulating tumor cells in metastatic breast cancer patients.
    Aktas B; Kasimir-Bauer S; Müller V; Janni W; Fehm T; Wallwiener D; Pantel K; Tewes M;
    BMC Cancer; 2016 Jul; 16():522. PubMed ID: 27456970
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation of hormone receptor status between circulating tumor cells, primary tumor, and metastasis in breast cancer patients.
    Kalinsky K; Mayer JA; Xu X; Pham T; Wong KL; Villarin E; Pircher TJ; Brown M; Maurer MA; Bischoff FZ
    Clin Transl Oncol; 2015 Jul; 17(7):539-46. PubMed ID: 25613123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of HER2 phenotype of circulating tumor cells in metastatic breast cancer: a retrospective study in 107 patients.
    Wallwiener M; Hartkopf AD; Riethdorf S; Nees J; Sprick MR; Schönfisch B; Taran FA; Heil J; Sohn C; Pantel K; Trumpp A; Schneeweiss A
    BMC Cancer; 2015 May; 15():403. PubMed ID: 25972110
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of circulating tumor cells according to immunohistochemically defined molecular subtypes in advanced breast cancer.
    Munzone E; Botteri E; Sandri MT; Esposito A; Adamoli L; Zorzino L; Sciandivasci A; Cassatella MC; Rotmensz N; Aurilio G; Curigliano G; Goldhirsch A; Nolè F
    Clin Breast Cancer; 2012 Oct; 12(5):340-6. PubMed ID: 23040002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic Impact of HER2 and ER Status of Circulating Tumor Cells in Metastatic Breast Cancer Patients with a HER2-Negative Primary Tumor.
    Beije N; Onstenk W; Kraan J; Sieuwerts AM; Hamberg P; Dirix LY; Brouwer A; de Jongh FE; Jager A; Seynaeve CM; Van NM; Foekens JA; Martens JW; Sleijfer S
    Neoplasia; 2016 Nov; 18(11):647-653. PubMed ID: 27764697
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hormone Receptor Status and HER2 Expression in Primary Breast Cancer Compared With Synchronous Axillary Metastases or Recurrent Metastatic Disease.
    Rossi S; Basso M; Strippoli A; Dadduzio V; Cerchiaro E; Barile R; D'Argento E; Cassano A; Schinzari G; Barone C
    Clin Breast Cancer; 2015 Oct; 15(5):307-12. PubMed ID: 25922284
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by RT-PCR and comparison to status of bone marrow disseminated cells.
    Fehm T; Hoffmann O; Aktas B; Becker S; Solomayer EF; Wallwiener D; Kimmig R; Kasimir-Bauer S
    Breast Cancer Res; 2009; 11(4):R59. PubMed ID: 19664291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial.
    Fehm T; Müller V; Aktas B; Janni W; Schneeweiss A; Stickeler E; Lattrich C; Löhberg CR; Solomayer E; Rack B; Riethdorf S; Klein C; Schindlbeck C; Brocker K; Kasimir-Bauer S; Wallwiener D; Pantel K
    Breast Cancer Res Treat; 2010 Nov; 124(2):403-12. PubMed ID: 20859679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phenotypic characterization of circulating tumor cells in triple negative breast cancer patients.
    Agelaki S; Dragolia M; Markonanolaki H; Alkahtani S; Stournaras C; Georgoulias V; Kallergi G
    Oncotarget; 2017 Jan; 8(3):5309-5322. PubMed ID: 28029660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiple biomarker expression on circulating tumor cells in comparison to tumor tissues from primary and metastatic sites in patients with locally advanced/inflammatory, and stage IV breast cancer, using a novel detection technology.
    Somlo G; Lau SK; Frankel P; Hsieh HB; Liu X; Yang L; Krivacic R; Bruce RH
    Breast Cancer Res Treat; 2011 Jul; 128(1):155-63. PubMed ID: 21499685
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metastatic breast carcinoma in pleural fluid: Correlation of receptor and HER2 status with the primary carcinoma-a pilot study.
    Francis IM; Alath P; George SS; Jaragh M; Al Jassar A; Kapila K
    Diagn Cytopathol; 2016 Dec; 44(12):980-986. PubMed ID: 27666130
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular profiling and predictive value of circulating tumor cells in patients with metastatic breast cancer: an option for monitoring response to breast cancer related therapies.
    Tewes M; Aktas B; Welt A; Mueller S; Hauch S; Kimmig R; Kasimir-Bauer S
    Breast Cancer Res Treat; 2009 Jun; 115(3):581-90. PubMed ID: 18679793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of hormonal receptor expression and HER2 status between circulating tumor cells and breast cancer metastases.
    Sanches SM; Braun AC; Calsavara VF; Barbosa PNVP; Chinen LTD
    Clinics (Sao Paulo); 2021; 76():e2971. PubMed ID: 34644733
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of estrogen and progesterone receptor status of circulating tumor cells and the primary tumor in metastatic breast cancer patients.
    Aktas B; Müller V; Tewes M; Zeitz J; Kasimir-Bauer S; Loehberg CR; Rack B; Schneeweiss A; Fehm T
    Gynecol Oncol; 2011 Aug; 122(2):356-60. PubMed ID: 21605893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of the hormone receptor status of circulating tumor cell subpopulations based on epithelial-mesenchymal transition: a proof-of-principle study on the heterogeneity of circulating tumor cells.
    Guan X; Ma F; Liu S; Wu S; Xiao R; Yuan L; Sun X; Yi Z; Yang H; Xu B
    Oncotarget; 2016 Oct; 7(40):65993-66002. PubMed ID: 27602758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discordant expression of hormone receptors and HER2 in breast cancer. A retrospective comparison of primary tumors with paired metachronous recurrences or metastases.
    Arapantoni-Dadioti P; Valavanis C; Gavressea T; Tzaida O; Trihia H; Lekka I
    J BUON; 2012; 17(2):277-83. PubMed ID: 22740206
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biomarkers characterization of circulating tumour cells in breast cancer patients.
    Nadal R; Fernandez A; Sanchez-Rovira P; Salido M; Rodríguez M; García-Puche JL; Macià M; Corominas JM; Delgado-Rodriguez M; Gonzalez L; Albanell J; Fernández M; Solé F; Lorente JA; Serrano MJ
    Breast Cancer Res; 2012 May; 14(3):R71. PubMed ID: 22554015
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular characterization of circulating tumor cells from patients with metastatic breast cancer reflects evolutionary changes in gene expression under the pressure of systemic therapy.
    Aaltonen KE; Novosadová V; Bendahl PO; Graffman C; Larsson AM; Rydén L
    Oncotarget; 2017 Jul; 8(28):45544-45565. PubMed ID: 28489591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) status in the fine needle aspirates of metastatic breast carcinomas.
    Monaco SE; Wu Y; Teot LA; Cai G
    Diagn Cytopathol; 2013 Apr; 41(4):308-15. PubMed ID: 22045649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-time HER2 status detected on circulating tumor cells predicts different outcomes of anti-HER2 therapy in histologically HER2-positive metastatic breast cancer patients.
    Zhang S; Li L; Wang T; Bian L; Hu H; Xu C; Liu B; Liu Y; Cristofanilli M; Jiang Z
    BMC Cancer; 2016 Jul; 16():526. PubMed ID: 27456503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 56.